Skip to content
ClinCalc Pro
Menu
Topical antihistamine / mast cell stabiliser (allergic conjunctivitis)

Olopatadine 0.1% Eye Drops (Opatanol)

Brand names: Opatanol

Olopatadine eye drops (Opatanol) are a topical ophthalmic antiallergic agent with dual antihistamine and mast cell stabilising activity, used to treat allergic conjunctivitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a selective histamine H1-receptor antagonist that also inhibits the release of inflammatory mediators from mast cells, relieving the itching and redness of ocular allergy.

Prescribing in practice

  • It provides both rapid symptom relief and a preventive effect, but is not a treatment for ocular infection and the underlying allergic trigger should be addressed where possible.
  • Contact lenses should be removed before instillation if the eyes are red, and the preservative may be absorbed by soft lenses.
  • Transient blurred vision after instillation may temporarily affect tasks such as driving.

Monitoring

Treatment is monitored clinically by reviewing symptom control during the period of allergen exposure.

Counselling the patient

  • The drops both relieve and help prevent allergy symptoms, so use them as your clinician directs.
  • Wait until any temporary blurring clears before driving or operating machinery.
  • Remove contact lenses before use and follow advice on when to reinsert them.

Evidence & guidelines

Dual-acting antihistamine and mast cell stabiliser drops are an established treatment for allergic conjunctivitis, supported by clinical trials and the SPC.

Reference: Opatanol SPC; BSACI Allergic Conjunctivitis Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.